1. Home
  2. NVCR vs TNDM Comparison

NVCR vs TNDM Comparison

Compare NVCR & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVCR
  • TNDM
  • Stock Information
  • Founded
  • NVCR 2000
  • TNDM 2006
  • Country
  • NVCR Switzerland
  • TNDM United States
  • Employees
  • NVCR N/A
  • TNDM N/A
  • Industry
  • NVCR Medical/Dental Instruments
  • TNDM Medical/Dental Instruments
  • Sector
  • NVCR Health Care
  • TNDM Health Care
  • Exchange
  • NVCR Nasdaq
  • TNDM Nasdaq
  • Market Cap
  • NVCR 2.3B
  • TNDM N/A
  • IPO Year
  • NVCR 2015
  • TNDM 2013
  • Fundamental
  • Price
  • NVCR $17.82
  • TNDM $19.16
  • Analyst Decision
  • NVCR Strong Buy
  • TNDM Buy
  • Analyst Count
  • NVCR 4
  • TNDM 15
  • Target Price
  • NVCR $37.50
  • TNDM $46.07
  • AVG Volume (30 Days)
  • NVCR 795.3K
  • TNDM 1.8M
  • Earning Date
  • NVCR 05-01-2025
  • TNDM 05-01-2025
  • Dividend Yield
  • NVCR N/A
  • TNDM N/A
  • EPS Growth
  • NVCR N/A
  • TNDM N/A
  • EPS
  • NVCR N/A
  • TNDM N/A
  • Revenue
  • NVCR $605,220,000.00
  • TNDM $940,203,000.00
  • Revenue This Year
  • NVCR $3.41
  • TNDM $8.70
  • Revenue Next Year
  • NVCR $9.24
  • TNDM $11.06
  • P/E Ratio
  • NVCR N/A
  • TNDM N/A
  • Revenue Growth
  • NVCR 18.82
  • TNDM 25.74
  • 52 Week Low
  • NVCR $11.70
  • TNDM $17.64
  • 52 Week High
  • NVCR $34.13
  • TNDM $53.69
  • Technical
  • Relative Strength Index (RSI)
  • NVCR 33.96
  • TNDM 31.64
  • Support Level
  • NVCR $18.23
  • TNDM $19.12
  • Resistance Level
  • NVCR $19.06
  • TNDM $21.15
  • Average True Range (ATR)
  • NVCR 0.80
  • TNDM 0.93
  • MACD
  • NVCR 0.02
  • TNDM 0.52
  • Stochastic Oscillator
  • NVCR 5.57
  • TNDM 38.77

About NVCR NovoCure Limited

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

Share on Social Networks: